ZYBERNO
Stock Report
Updated Sep 1, 2026

Zeo ScientifiX, Inc. (ZEOX)

Healthcare • OTC

$1.32

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
Zeo ScientifiX, Inc. (ZEOX) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-721.8%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.27x)
Operating Margin (Operational Efficiency):CRITICAL (-69.2%)
Return on Capital (Capital Efficiency):CRITICAL (-336.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Zeo ScientifiX, Inc. (ZEOX) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:1.32
Market Cap:$10.24M

Valuation Multiples (3)

P/B Ratio:14.38x
P/S Ratio:1.43x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$10.63M

Price Action & Momentum (3)

Momentum Percentile:35 / 100
% of 52-Week High:44.1%
B. Profitability Assessment

Return Metrics (5)

ROA:-213.3%
Reinvestment Rate:1.4%
Fundamental Growth Rate (g):-4.5%

Margin Analysis (3)

Operating Margin Ttm:-69.2%
Net Margin Ttm:-71.8%
Ebitda Margin:-68.2%

TTM Performance (3)

Gross Margin Ttm:81.2%
Operating Margin Ttm:-69.2%
Net Margin Ttm:-71.8%

Yield Metrics (2)

Earnings Yield:-$54.16
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:91.5%
Latest Earnings Filed:2026-06-15

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):5.2%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.05x
Quick Ratio:0.83x
Cash Ratio:0.59x

Leverage Analysis (3)

Debt To Equity Ttm:0.27x
Debt-to-Equity Ratio:0.27x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-74.81x
Times Interest Earned:-74.81

Capital Structure (4)

Working Capital:155,000.00
Cash And Cash Equivalents:1,846,000.00
Long Term Debt:$96.00K
Net Debt:$393.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $7.16M
Linear Growth: 5.2%
📊 Click to view full ZEOX Revenue analysis & methodology →
Cost Of Revenue Ttm:$1.35M

Profitability Breakdown (2)

Gross profit TTM: $5.81M
Linear Growth: 2.2%
📊 Click to view full ZEOX Gross Profit analysis & methodology →
-$4.95M

Bottom Line Performance (3)

-$5.14M
Income Before Tax:$0.00
Ebitda Ttm:-4,879,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:150,000.00
Sga Expense:10,762,000.00
Income Tax Expense:$0.00
Interest Expense:72,000.00

Expense Ratios (3)

R And D To Revenue Percentage:5.8%
Sga To Revenue Percentage:417.0%
Ebitda Margin:-68.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.89M
Current Assets:$3.27M
Ppe Net:609,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:3,174,000.00
Current Liabilities:3,111,000.00
Long Term Debt:$96.00K
Short Term Debt:$2.14M

Equity & Capital (3)

Equity:$712.00K
Retained Earnings:-$68.73M
Common Stock:2,500,000,000.00

Working Capital Items (3)

Accounts Receivable:276,000.00
Inventory:686,000.00
Accounts Payable:2,143,000.00

Special Items (2)

Contract Liabilities:671,000.00
Stock Based Compensation:590,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$718.00K-$741.00K

Investment Activities (1)

Investing Cash Flow:-$14.00K

Financing Activities (3)

Financing Cash Flow:$1.29M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:1,300,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:74,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.76
-$0.76
Earnings Per Share Ttm:-$0.66

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.92
Operating Cash Flow Per Share:-$0.09

Book Value & Capital (2)

Book Value Per Share:$0.09
Cash Per Share:0.24

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:2.97x
Working Capital Turnover Ttm:46.17x

Receivables Management (2)

Receivables Turnover Ttm:25.93x
Days Sales Outstanding Ttm:14.08

Inventory Management (2)

Inventory Turnover Ttm:1.96x
Days Inventory Outstanding Ttm:185.89

Payables & Cash Cycle (2)

Days Payable Outstanding:580.69
Cash Conversion Cycle:-380.73
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:1.4%
Fundamental Growth Rate (g):-4.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):5.2%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):2.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:ZEOX
Company Name:Zeo ScientifiX, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:7.76M
Shares Outstanding Basic:7.76M
Shares Outstanding Diluted:7.76M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 14:29:09 UTC
Data Timestamp:2026-08-21T12:24:41.512830
Scroll to Top